An Open-Label Phase ½ Study of INCB039110 in Combination With Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
An Open-Label Phase ½ Study of INCB039110 in Combination With Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.